Trial Site Detail
Drug: |
CB-839 |
|||
|---|---|---|---|---|
Trial: |
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Active, not recruiting |
|||
MD Anderson Cancer Center1505 Holcombe Blvd. |
Principal Investigator: |
Vivek Subbiah |
|---|---|
Contact: |
Site Public Contact: 877-632-6789 askmdanderson@mdanderson.org |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
MD Anderson Cancer Center Website: |
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.